Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antimicrobial resistance grants

This article was originally published in The Tan Sheet

Executive Summary

CDC announces availability of roughly $600,000 in grant funding for fiscal 2002 for applied research aimed at "prevention and control of the emergence and spread of antimicrobial resistance" in U.S. Program will focus on validation of National Committee for Clinical Laboratory Standards breakpoints for human pathogens of public health importance, according to June 4 Federal Register notice. Research, in form of three separate $200,000 grants, is expected to begin Aug. 30 and continue for up to three years, CDC says. Completed application forms, available on 1CDC Web site, are due July 16...

You may also be interested in...



Sales Already Growing As Vascepa Secures Cardio Approval

Company forecast 2020 sales as high as $700m as regulator grants broad label.

Belgium Outlaws OTC Cough And Cold Combination Drugs

Safety concerns prompt Belgium's drug regulator to order all OTC fixed combination products for coughs and colds removed from shelves.

Allegations Of EU Notified Body Fees Having Escalated And Of Being Unpredictable

US medtech companies are worried EU notified bodies have too much freedom over setting their fees, accusing them of lacking transparency and being inconsistent with what they charge. They also allege that notified body practices mean some products will miss the four-year grace period.


Topics

UsernamePublicRestriction

Register

PS094107

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel